Tatiana Mironenko
Overview
Explore the profile of Tatiana Mironenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
6560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vis D, Jaaks P, Aben N, Coker E, Barthorpe S, Beck A, et al.
Cell Rep Med
. 2024 Aug;
5(8):101687.
PMID: 39168097
Combining drugs can enhance their clinical efficacy, but the number of possible combinations and inter-tumor heterogeneity make identifying effective combinations challenging, while existing approaches often overlook clinically relevant activity. We...
2.
Bashi A, Coker E, Bulusu K, Jaaks P, Crafter C, Lightfoot H, et al.
Cancer Discov
. 2024 Mar;
14(5):846-865.
PMID: 38456804
Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by...
3.
Jaaks P, Coker E, Vis D, Edwards O, Carpenter E, Leto S, et al.
Nature
. 2022 Feb;
603(7899):166-173.
PMID: 35197630
Combinations of anti-cancer drugs can overcome resistance and provide new treatments. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations...
4.
Goncalves E, Segura-Cabrera A, Pacini C, Picco G, Behan F, Jaaks P, et al.
Mol Syst Biol
. 2020 Jul;
16(7):e9405.
PMID: 32627965
Low success rates during drug development are due, in part, to the difficulty of defining drug mechanism-of-action and molecular markers of therapeutic activity. Here, we integrated 199,219 drug sensitivity measurements...
5.
Iorio F, Knijnenburg T, Vis D, Bignell G, Menden M, Schubert M, et al.
Cell
. 2016 Jul;
166(3):740-754.
PMID: 27397505
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is...
6.
Gill S, Travers J, Pshenichnaya I, Kogera F, Barthorpe S, Mironenko T, et al.
PLoS One
. 2015 Oct;
10(10):e0140988.
PMID: 26505995
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP)...
7.
Garnett M, Edelman E, Heidorn S, Greenman C, Dastur A, Lau K, et al.
Nature
. 2012 Mar;
483(7391):570-5.
PMID: 22460902
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover...
8.
Dalgliesh G, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al.
Nature
. 2010 Jan;
463(7279):360-3.
PMID: 20054297
Clear cell renal cell carcinoma (ccRCC) is the most common form of adult kidney cancer, characterized by the presence of inactivating mutations in the VHL gene in most cases, and...
9.
Tarpey P, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, et al.
Nat Genet
. 2009 Apr;
41(5):535-43.
PMID: 19377476
Large-scale systematic resequencing has been proposed as the key future strategy for the discovery of rare, disease-causing sequence variants across the spectrum of human complex disease. We have sequenced the...
10.
van Haaften G, Dalgliesh G, Davies H, Chen L, Bignell G, Greenman C, et al.
Nat Genet
. 2009 Mar;
41(5):521-3.
PMID: 19330029
Somatically acquired epigenetic changes are present in many cancers. Epigenetic regulation is maintained via post-translational modifications of core histones. Here, we describe inactivating somatic mutations in the histone lysine demethylase...